Hereditary angioedema (HAE) is a rare genetic disease that reduces C1 inhibitor levels and impacts the regulation of several pathways involved in dilation of the blood vessels and results in recurrent episodes of severe swelling. touchIMMUNOLOGY were delighted to speak with Dr. William R. Lumry (UT Southwestern Medical Center, TX, USA) around the unmet needs in the treatment of HAE and how the approval of lanadelumab has already impacted the treatment paradigm in this indication.
The abstract ‘Efficacy of lanadelumab at fixed and modified dosing regimens in patients aged 2 to <12 years old with hereditary angioedema (HAE) in the phase 3, open-label, multicenter SPRING Study.‘ (Abstract number: AB140) was presented at AAAAI 2023, February 24–27, 2022, #AAAAI2023.
Questions
- Could you tell us a little about hereditary angioedema (HAE) and the unmet needs in its treatment? (0:42)
- What impact has lanadelumab already had on the treatment paradigm for HAE? (3:29)
Disclosures: William R. Lumry discloses consulting for: Astria, BioCryst, Biomarin, CSL Behring, Express Scripts/CVS, Fresenius Kabi, Intellia, Kalvista, Magellan, Optum, Pharming, Pharvaris, and Shire/Takeda; receiving grant/research support from: Astria, BioMarin, CSL Behring, Intellia, Grifols, Ionis, Kalvista, and Shire/Takeda; serving on advisory boards for: Astria, BioCryst, Biomarin, CSL Behring, Express Scripts/CVS, Fresenius Kabi, Intellia, Kalvista, Magellan, Optum, Pharming, Pharvaris, and Shire/Takeda; receiving honoraria for consultancy and speaker’s bureaus and participating in speaker’s bureaus with: BioCryst, CSL Behring, Optinose, Pharming, Shire/Takeda, Grifols, Astra Zeneca, Sanofi/Regeneron, and GSK.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the American Academy of Allergy Asthma & Immunology Annual Meeting 2023.
Click here for more content on allergic conditions.
